Could a new eye drop beat an old favorite for glaucoma?
NCT ID NCT07617532
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new eye drop, DNN.31.19.026, against a standard treatment (Cosopt) for people with high eye pressure or open-angle glaucoma. About 336 adults will use the drops twice daily for 56 days. The main goal is to see if the new drop lowers eye pressure better and is just as safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNN.31.19.026 eye drops
What this could lead to
If successful, this could offer a new, safe option for lowering eye pressure in people with glaucoma or ocular hypertension.
What could go wrong
This is a Phase 3 trial, but it's not yet recruiting. The new eye drops may not lower pressure better than the existing drug Cosopt, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.